LAG3 and melanoma: This finding is in line with previous studies of anti–PD-(L)1 combinations; a similar incidence of TRAEs was reported for combined nivolumab (anti–PD-1) and relatlimab (anti–LAG-3) treatment for patients with advanced melanoma who are treatment-naïve (RELATIVITY-047) and PD-(L)1–experienced (RELATIVITY-020; refs. 4, 34).